{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:40:58Z","timestamp":1761093658986,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.bcmd.2020.102418","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T19:38:55Z","timestamp":1582573135000},"page":"102418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy"],"prefix":"10.1016","volume":"82","author":[{"given":"David J.","family":"Kuter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wajnrajch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betina","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Chertkoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2020.102418_bb0005","series-title":"Williams Hematology","first-page":"1121","article-title":"Gaucher disease and related lysosomal storage diseases","author":"Zimran","year":"2016"},{"key":"10.1016\/j.bcmd.2020.102418_bb0010","series-title":"The Online Metabolic and Molecular Basis of Inherited Disease","first-page":"1","article-title":"Gaucher disease","author":"Grabowski","year":"2010"},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2020.102418_bb0015","first-page":"82","article-title":"Management of Gaucher disease: enzyme replacement therapy","volume":"12","author":"Zimran","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.bcmd.2020.102418_bb0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymgme.2015.09.002","article-title":"Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States","volume":"117","author":"Balwani","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2020.102418_bb0025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.15402","article-title":"How we manage Gaucher disease in the era of choices","volume":"182","author":"Revel-Vilk","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2020.102418_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bcmd.2017.08.016","article-title":"Recent advances and future challenges in Gaucher disease","volume":"68","author":"Zimran","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2020.102418_bb0035","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system","volume":"5","author":"Shaaltiel","year":"2007","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.bcmd.2020.102418_bb0040","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nbt0612-472","article-title":"First plant-made biologic approved","volume":"30","author":"Fox","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2020.102418_bb0045","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","article-title":"Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2020.102418_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128986","article-title":"Pharmacokinetics of novel plant cell-expressed taliglucerase alfa in adult and pediatric patients with Gaucher disease","volume":"10","author":"Abbas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2020.102418_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004792","article-title":"A plant-derived recombinant human glucocerebrosidase enzyme\u2014a preclinical and phase I investigation","volume":"4","author":"Aviezer","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2020.102418_bb0060","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ajh.24369","article-title":"Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naive patients with Gaucher disease","volume":"91","author":"Zimran","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2020.102418_bb0065","article-title":"Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naive patients with Gaucher disease","author":"Zimran","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2020.102418_bb0070","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.24399","article-title":"Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase","volume":"91","author":"Pastores","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2020.102418_bb0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bcmd.2014.05.004","volume":"53","author":"Pastores","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2020.102418_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bcmd.2014.10.002","article-title":"Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease","volume":"54","author":"Zimran","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2020.102418_bb0085","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bcmd.2016.10.005","article-title":"Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naive or previously treated with imiglucerase","volume":"68","author":"Zimran","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2020.102418_bb0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","article-title":"Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease","volume":"44","author":"Hollak","year":"2010","journal-title":"Blood Cells Mol. Dis."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979620300668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979620300668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:35:25Z","timestamp":1761050125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979620300668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":18,"alternative-id":["S1079979620300668"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2020.102418","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2020.102418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102418"}}